Titlebook: Immunotherapy and Biomarkers in Neurodegenerative Disorders; Martin Ingelsson,Lars Lannfelt Book 2016 Springer Science+Business Media New

案发地点

Immunotherapy Against Amyloid-β in Alzheimer’s Disease: An Overviewents are urgently needed, and the amyloid cascade hypothesis thus far provides the best basis for the development of such therapies. Preclinical studies in mouse models of AD showed that immunization with amyloid-β (Aβ) as well as passive vaccination with monoclonal antibodies against Aβ may be effe

故意钓到白杨

Active Immunization Against the Amyloid-β Peptideeveral therapies have been approved to treat AD, all of which provide modest effect on the symptoms of the illness but without slowing or halting the underlying disease processes. Since the last of these therapies was approved, the largest research effort has been devoted to developing therapies tar

激怒某人

Immunotherapy Against N-Truncated Amyloid-β Oligomerser’s disease (AD), which is characterized by the presence of extracellular amyloid-Aβ plaques and intraneuronal neurofibrillary tangles consisting of tau protein. Numerous studies have demonstrated that the amyloid cascade triggers tau pathology, with tau being intimately involved in the molecular m

南极

mitral-valve

Immunotherapy Against α-Synuclein Pathologythat affects approximately 1.5 million people in the USA and 1 % of people over 60 years old. Both vaccination and passive immunization approaches with antibodies targeting alpha-synuclein (α-syn) have been extensively explored, especially since the discovery that this protein may propagate from cel

Musket

Extracellular α-Synuclein as a Target for Immunotherapygrowing body of evidence suggests that α-synuclein, an intra-neuronal protein, is exocytosed from neurons and that extracellular α-synuclein could mediate the major pathological changes in PD, such as neurodegeneration, neuroinflammation, and progressive spreading of protein inclusions. Here, we rev

空气

从属

Tau Immunotherapystudies by several groups have shown efficacy of various active and passive approaches in reducing pathological tau proteins. Clinical trials are clearly warranted and a few have already been initiated. However, much remains to be clarified regarding the mechanisms of action and how efficacy can be

水獭

定点